Neuro

American Brain Tumor Association Announces $1.3 Million in New Funding to Accelerate Adult and Pediatric Brain Tumor Research

Retrieved on: 
Wednesday, November 8, 2023
Soma, American Brain Tumor Association, Biomarker, Neuro, History, MD, Soma Sengupta, ABTA, Research, Chapel Hill, Mount Sinai, Brain, DNA repair, Icahn School of Medicine at Mount Sinai, Patient, Doctor of Philosophy, Joel, DNA, Medical imaging, Pharmaceutical industry, Citrus

CHICAGO, Nov. 8, 2023 /PRNewswire/ -- The American Brain Tumor Association (ABTA) today announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages. Dedicated to advancing the field of neuro-oncology and accelerating the discovery of life-saving treatments, the ABTA is proud to have invested more than $35 million, to approximately 700 researchers and 800 projects, to date.

Key Points: 
  • CHICAGO, Nov. 8, 2023 /PRNewswire/ -- The American Brain Tumor Association (ABTA) today announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages.
  • ABTA's high-risk, high-reward research grants have contributed to significant breakthroughs in treating brain tumors.
  • This year's slate of research projects investigates biomarkers, DNA damage and repair mechanisms, gene therapies, and more, across adult and pediatric primary brain tumors and metastatic brain cancers.
  • Research Collaboration Grants are two-year, $200,000 grants awarded for multi-investigator and multi-institutional brain tumor collaborative research projects.

Zscaler Accelerates AI Innovations with Appointments of Two Prominent Tech Industry Disruptors

Retrieved on: 
Monday, November 6, 2023
Cloud, Artificial Intelligence for IT Operations, EVP, Engineering, B2C, SVP, Neuro, Microsoft, Organization, CERN, Generative, Deep learning, Artificial intelligence, Sabar people, Learning, Trust, Salesforce, Growth, Machine learning, Gamer, Zero trust security model, ML, Investment, Automation, Marketing, ZS, Palo Alto Networks, SAN, Medical device, Sales, Advantest, AI, Zscaler

Working in collaboration, Claudionor Coelho Jr. joins as Chief AI Officer and Mohamed Shabar joins as EVP, Data & AI Platforms.

Key Points: 
  • Working in collaboration, Claudionor Coelho Jr. joins as Chief AI Officer and Mohamed Shabar joins as EVP, Data & AI Platforms.
  • These strategic additions to the Zscaler executive team reinforce the company’s commitment to driving rapid innovation in advanced applied Machine Learning (ML), and AI to help define the future of cloud-based security technologies.
  • “We are delighted that Mohamed and Claudionor are joining the Zscaler family to drive the vision and implementation of advanced AI technologies for the world’s largest cloud security platform,” said Syam Nair, Chief Technology Officer for Zscaler.
  • “I’m thrilled to join the visionary team at Zscaler,” said Mohamed Shabar, EVP, Data & AI Platforms, Zscaler.

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, Survival, Action, Biomarker, Neuro, MOS, DMG, SNO, Conference, CNS, Central nervous system, ONC201, Annual general meeting, ACTION, European Association for the Study of the Liver, Pakistan Society of Neuro-Oncology, Cancer Discovery (journal), Patient, Human, Completeness, Pharmaceutical industry

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update.
  • Chimerix reported a net loss of $24.0 million, or $0.27 per basic and diluted share, for the third quarter of 2023.
  • Research and development expenses increased to $17.4 million for the third quarter of 2023, compared to $15.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a business update today at 8:30 a.m.

Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration

Retrieved on: 
Tuesday, October 31, 2023
Genomics, University of California, Irvine Medical Center, Stanford University, CONVERGE, Neuro, Hallucination, Neuroanatomy, Deficit spending, Research, University, Artificial intelligence, Weill Cornell Medicine, Drug discovery, Partnership, DSM-IV codes, Delusion, Cornell University, Patient, Diagnosis, SAN, Pharmaceutical industry, Medical device, Schizophrenia, Biotechnology

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.
  • By combining their respective strengths and resources, Verge Genomics and the Pritzker Consortium aim to make substantial strides in the field of schizophrenia research.
  • "We are thrilled to embark on this transformative journey alongside Verge Genomics, combining their AI-powered CONVERGE platform with the invaluable resources of the Pritzker Neuropsychiatric Disorders Research Consortium.
  • This includes the Pritzker Brain Bank, known for stringent subject selection and comprehensive metadata, coupled with deep expertise in human structural and functional neuroanatomy,” said Richard M. Myers, Ph.D., Co-Project Leader, Pritzker Neuropsychiatric Disorders Research Consortium.

Advanced Scanners Inc. Announces Company Rebrand & New Name Effective Today: VISIE™ Inc.

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, Technology, Health, Health Technology, Other Technology, Medical Devices, Research, Software, Surgery, Science, Hardware, 3D, Spine, Neuro, Hope, MD, Doctor of Philosophy, MBA, Multimedia, Surgeon, Marketing, Deep tech, PT, Navy Precision Optical Interferometer, Darkness, Patient, Hospital, Brigham, 3D printing, Cryptocurrency, Dentistry

Advanced Scanners Inc., a 3D computer vision company developing a deep tech optical scanner for orthopedic, neuro, and spine surgery, announces a company rebrand.

Key Points: 
  • Advanced Scanners Inc., a 3D computer vision company developing a deep tech optical scanner for orthopedic, neuro, and spine surgery, announces a company rebrand.
  • Effective immediately, Advanced Scanners will be known as VISIE Inc.
  • View the full release here: https://www.businesswire.com/news/home/20231101737243/en/
    The company makes this announcement after coming out of a 90-day stealth period.
  • In August, the company teased, “From Darkness Comes New Light | 11.01.23,” on its website and LinkedIn, raising eyebrows around the medtech startup industry.

Neuronavigation Systems Market size to grow by USD 227.65 million from 2023-2028 | Apollo Hospitals Enterprise Ltd., B.Braun SE, Brainlab AG, and more among the key companies in the market - Technavio

Retrieved on: 
Monday, November 6, 2023
Research, Optics, Incidence, KARL, Neuro, Lexmark, Abdominal ultrasonography, ROW, Prevalence, Roper Technologies, Zimmer Biomet, Life expectancy, Growth, Stryker Corporation, Risk, Hospital, DSM-IV codes, SE, HOB GmbH & Co KG, Center for Urban and Regional Analysis, Lens, Essential tremor, USD, Segmental analysis (biology), Medtronic, Retail, Generic drug, Mobile phone, Pet industry, Geography

The majority of neuronavigation systems in the neuro-navigation systems market currently rely on optical tracking technology.

Key Points: 
  • The majority of neuronavigation systems in the neuro-navigation systems market currently rely on optical tracking technology.
  • The increased demand for neuronavigation systems is, in turn, driving growth in the global neuronavigation systems market during the forecast period.
  • Download the sample report to gain access to this information
    Neurofeedback Systems Market : The neurofeedback systems market share is expected to increase by USD 514.64 million from 2021 to 2026.
  • Detailed information on factors that will drive the growth of the neuronavigation systems market between 2024 and 2028.

INSIGHTEC ANNOUNCES NEW CATEGORY I CPT® CODE FROM AMA FOR NEURO PROCEDURES USING MR-GUIDED FOCUSED ULTRASOUND

Retrieved on: 
Thursday, November 2, 2023
FDA, Cat, Essential tremor, Tremor, Parkinson's disease, American Association of Neurological Surgeons, Neuro, Physician, American Medical Association, Congress, MD, CNS, Health, High-intensity focused ultrasound, AMA, AANS, Congress of Neurological Surgeons, DSM-IV codes, Patient, Medical imaging, Medical device, Insightec

HAIFA, Israel and MIAMI, Nov. 2, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that the editorial panel of the American Medical Association (AMA) approved their application to establish a new Category (Cat) I Current Procedural Terminology (CPT®) code to facilitate reimbursement for MR-guided focused ultrasound (MRgFUS) ablation of neurological targets. The Cat I CPT® code will be included in the next CPT® codebook and expected to be effective January 1, 2025.

Key Points: 
  • The Cat I CPT® code will be included in the next CPT® codebook and expected to be effective January 1, 2025.
  • "We've long known that focused ultrasound has a significant and valuable role in treating patients with neurological disorders.
  • "This approval can also lead to expanded access to focused ultrasound for US patients," says Dee Kolanek, vice president of market access and reimbursement for Insightec.
  • Focused ultrasound, which was pioneered by Insightec, is FDA approved to treat essential tremor and Parkinsonian tremor.

Leveraging Digital Biomarkers to Generate Real-World Physiological and Behavioral Data in CNS Clinical Studies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 30, 2023
Alzheimer's disease, Central nervous system disease, Biomarker, Neuro, Disease, Doctor of Philosophy, CNS, Health, HIV disease progression rates, Artificial intelligence, Caregiver, Database, Schizophrenia, Machine learning, Neurology, ML, EEG, Neuropsychiatry, Patient, Bias, Diagnosis, Central nervous system, Medical imaging, Nursing, Cumulus cloud

TORONTO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into an (artificial intelligence) AI-based, multi-domain digital biomarker platform that is currently being leveraged in neurology and neuropsychiatry clinical trials. To date, the lack of objective measures in central nervous system (CNS) clinical studies has resulted in less than 6% of drugs in this space making it to market. Many of the validated cognitive assessments today are paper-based, introducing the potential for bias and limiting ethnic and geographic diversity in clinical studies. An additional challenge facing CNS studies is the higher-than-average patient drop-out rates, in large part due to the burden associated with attending clinical site visits.

Key Points: 
  • The featured speakers will discuss the power of longitudinal EEG data synchronized with behavioral assessment data and how this can accelerate clinical studies, saving time and budget.
  • TORONTO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into an (artificial intelligence) AI-based, multi-domain digital biomarker platform that is currently being leveraged in neurology and neuropsychiatry clinical trials.
  • Many of the validated cognitive assessments today are paper-based, introducing the potential for bias and limiting ethnic and geographic diversity in clinical studies.
  • An additional challenge facing CNS studies is the higher-than-average patient drop-out rates, in large part due to the burden associated with attending clinical site visits.

Parker University Celebrates National Massage Therapy Awareness Week® October 22-28, 2023

Retrieved on: 
Monday, October 23, 2023
Dallas Cowboys, Human, System, Ford Center, Neuro, Dallas, Star, Weight gain, Massage, Veteran, AMTA, Athlete, PTSD, Learning, Licensure, Curriculum, Student, Sleep, Swelling, Fascia, Candy, Headache, Anxiety, Patient, Cancer, Parker University, Neck, Arthritis, Ford Center at The Star, Health care, Nursing, White Rock Lake, Acupressure

Dallas, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Every year, the American Massage Therapy Association (AMTA) celebrates National Massage Therapy Awareness Week® (NMTAW)!

Key Points: 
  • Dallas, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Every year, the American Massage Therapy Association (AMTA) celebrates National Massage Therapy Awareness Week® (NMTAW)!
  • Taking place October 22-28, 2023, this dedicated week for massage therapists across the U.S. recognizes and promotes the many health benefits of Massage Therapy.
  • Parker University joins the industry’s cause and informs potential students about its prestigious, one-of-a-kind Massage Therapy certificate program.
  • Gregory May, Parker University’s Massage Therapy Program Director, shares, “Our curriculum doesn’t stop at learning the basics of Swedish massage like most programs.

Luminopia Named to TIME’s List of the Best Inventions of 2023

Retrieved on: 
Tuesday, October 24, 2023
Software, Family, Optical, Consumer, Technology, Medical Devices, Health Technology, Clinical Trials, Children, Neurology, Audio, Video, Wearables, Mobile Technology, Health, FDA, VR, Ageing, Neuro, TIME, Invention, Entrepreneurship, Amblyopia, Virtual reality, Hospital, Paratriathlon, Eye, Algorithm, AI, Atropine, Patient, Randomized controlled trial, Pharmaceutical industry, Telescopic sight

Luminopia, Inc., a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, today announced that the company’s lead product, Luminopia, was named one of TIME’s Best Inventions of 2023.

Key Points: 
  • Luminopia, Inc., a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, today announced that the company’s lead product, Luminopia, was named one of TIME’s Best Inventions of 2023.
  • Luminopia is the first FDA-approved1 digital therapeutic for a neuro-visual disorder, indicated to improve vision in children, aged 4-7, with amblyopia (lazy eye).
  • “Despite the pace of technological advancements today, there has been little innovation in the treatment of lazy eye for several decades.
  • Of the new list, TIME’s editors shared: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)—including the world's most powerful supercomputer, a game-changing entertainment venue, and a new shape—that are changing how we live, work, play, and think about what’s possible.”
    See the full list of TIME’s Best Inventions of 2023 here: time.com/best-inventions-2023
    To learn more about Luminopia, visit luminopia.com .